Skip to content
2000
Volume 25, Issue 5
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Introduction

Adipokine irregularity leads to inflammation, endothelial dysfunction, insulin resistance (IR), and Non-Alcoholic Fatty Liver Disease (NAFLD). Previous studies linked NOV/CCN3 to obesity, IR, and inflammation, but no research has explored the connection between CCN3 serum levels and NAFLD.

Methods

This case-control study assessed CCN3, IL-6, adiponectin, and TNF-α serum levels in 80 NAFLD patients and 80 controls using ELISA kits. Biochemical parameters were measured with commercial kits and an auto analyzer.

Results

NAFLD patients exhibited significantly higher CCN3 (2399.85 ± 744.53 . 1712.84 ± 478.19 ng/ml), TNF-α, and IL-6 levels, and lower adiponectin levels compared to controls (<0.0001). In the NAFLD group, CCN3 showed positive correlations with FBG, insulin, HOMA-IR, and TNF-α. Binary logistic regression analysis revealed increased NAFLD risk in the adjusted model (OR [95% CI] = 1.220 [1.315-1.131]). A CCN3 cut-off value of 1898.0050 pg/mL differentiated NAFLD patients from controls with 78.8% sensitivity and 73.2% specificity.

Conclusion

It was found that elevated CCN3 serum levels directly correlate with NAFLD incidence and inflammation markers (IL-6 and TNF-α). CCN3 could serve as a potential biomarker for NAFLD, but further research is needed to validate this finding and assess its clinical utility.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240285539240214111947
2024-02-23
2025-09-03

  • From This Site

    /content/journals/cmm/10.2174/0115665240285539240214111947
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CaturanoA. AciernoC. NevolaR. Non-alcoholic fatty liver disease: From pathogenesis to clinical impact.Processes20219113510.3390/pr9010135
     [Google Scholar]
  2. Vancells LujanP. Viñas EsmelE. Sacanella MeseguerE. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development.Nutrients2021135144210.3390/nu13051442 33923255
     [Google Scholar]
  3. KasperP. MartinA. LangS. NAFLD and cardiovascular diseases: A clinical review.Clin. Res. Cardiol.2021110792193710.1007/s00392‑020‑01709‑7 32696080
     [Google Scholar]
  4. WuW. HuX. ZhouX. KlenoticP.A. ZhouQ. LinZ. Myeloid deficiency of CCN3 exacerbates liver injury in a mouse model of nonalcoholic fatty liver disease.J. Cell Commun. Signal.201812138939910.1007/s12079‑017‑0432‑4 29214510
     [Google Scholar]
  5. LiuL. ShiZ. JiX. Adipokines, adiposity, and atherosclerosis.Cell. Mol. Life Sci.202279527210.1007/s00018‑022‑04286‑2 35503385
     [Google Scholar]
  6. EscotéX. Gómez-ZoritaS. López-YoldiM. Role of omentin, vaspin, cardiotrophin-1, TWEAK and NOV/CCN3 in obesity and diabetes development.Int. J. Mol. Sci.2017188177010.3390/ijms18081770 28809783
     [Google Scholar]
  7. AdolphT. GranderC. GrabherrF. TilgH. Adipokines and non-alcoholic fatty liver disease: Multiple interactions.Int. J. Mol. Sci.2017188164910.3390/ijms18081649 28758929
     [Google Scholar]
  8. JungU. ChoiM.S. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.Int. J. Mol. Sci.20141546184622310.3390/ijms15046184 24733068
     [Google Scholar]
  9. FranciscoV. SanzM.J. RealJ.T. Adipokines in non-alcoholic fatty liver disease: Are we on the road toward new biomarkers and therapeutic targets?Biology2022118123710.3390/biology11081237 36009862
     [Google Scholar]
  10. OhgawaraT. KubotaS. KawakiH. Association of the metastatic phenotype with CCN family members among breast and oral cancer cells.J. Cell Commun. Signal.20115429129910.1007/s12079‑011‑0133‑3 21499980
     [Google Scholar]
  11. SacerdotiD. SinghS.P. SchragenheimJ. BellnerL. VanellaL. RaffaeleM. Development of NASH in obese mice is confounded by adipose tissue increase in inflammatory NOV and oxidative stress.Int. J. Hepatol.20182018348410710.1155/2018/3484107
     [Google Scholar]
  12. Fadhil JaafarA. AfrishamR. FadaeiR. CCN3/NOV serum levels in coronary artery disease (CAD) patients and its correlation with TNF-α and IL-6.BMC Res. Notes202316130610.1186/s13104‑023‑06590‑x 37919772
     [Google Scholar]
  13. TwiggS.M. Regulation and bioactivity of the CCN family of genes and proteins in obesity and diabetes.J. Cell Commun. Signal.201812135936810.1007/s12079‑018‑0458‑2 29411334
     [Google Scholar]
  14. Hamdan AlshganbeeM.F. NabatchianF. FarrokhiV. FadaeiR. MoradiN. AfrishamR. A positive association of serum CCN5/WISP2 levels with the risk of developing gestational diabetes mellitus: A case-control study.J. Physiol. Sci.20237312210.1186/s12576‑023‑00879‑z 37794318
     [Google Scholar]
  15. JuL. SunY. XueH. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis.Sci. Rep.2020101320110.1038/s41598‑020‑60138‑8 32081971
     [Google Scholar]
  16. SongY. LiC. LuoY. CCN6 improves hepatic steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis.Liver Int.202343235736910.1111/liv.15430 36156376
     [Google Scholar]
  17. RenJ. WangX. ParryS.N. Targeting CCN2 protects against progressive non-alcoholic steatohepatitis in a preclinical model induced by high-fat feeding and type 2 diabetes.J. Cell Commun. Signal.202216344746010.1007/s12079‑022‑00667‑1 35038159
     [Google Scholar]
  18. JungT.W. KangC. GohJ. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling.J. Cell. Physiol.201823386077608710.1002/jcp.26449 29319180
     [Google Scholar]
  19. LiJ.Y. WangY.D. QiX.Y. Serum CCN3 levels are increased in type 2 diabetes mellitus and associated with obesity, insulin resistance and inflammation.Clin. Chim. Acta2019494525710.1016/j.cca.2019.03.006 30876855
     [Google Scholar]
  20. MartinerieC. GarciaM. DoT.T.H. NOV/CCN3: A new adipocytokine involved in obesity-associated insulin resistance.Diabetes20166592502251510.2337/db15‑0617 27284105
     [Google Scholar]
  21. ParadisR. LazarN. AntinozziP. PerbalB. ButeauJ. Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.PLoS One201385e6495710.1371/journal.pone.0064957 23705021
     [Google Scholar]
  22. RiserB.L. NajmabadiF. PerbalB. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.J. Cell Commun. Signal.201041395010.1007/s12079‑010‑0085‑z 20195391
     [Google Scholar]
  23. TrepianaJ. Gómez-ZoritaS. Fernández-QuintelaA. GonzálezM. PortilloM.P. Effects of resveratrol and its analogue pterostilbene, on NOV/CCN3 adipokine in adipose tissue from rats fed a high-fat high-sucrose diet.J. Physiol. Biochem.201975327528310.1007/s13105‑019‑00680‑w 30972698
     [Google Scholar]
  24. PakradouniJ. Le GoffW. CalmelC. Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders.PLoS One201386e6678810.1371/journal.pone.0066788 23785511
     [Google Scholar]
/content/journals/cmm/10.2174/0115665240285539240214111947
Loading
CCN3/NOV Serum Levels in Non-alcoholic Fatty Liver Disease (NAFLD) Patients in Comparison with the Healthy Group and its Correlation with TNF-α and IL-6
Current Molecular Medicine 25, 605 (2025); https://doi.org/10.2174/0115665240285539240214111947
/content/journals/cmm/10.2174/0115665240285539240214111947
/content/journals/cmm/10.2174/0115665240285539240214111947
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): adipokine; endothelial dysfunction; inflammatory cytokines; insulin resistance; non-alcoholic fatty liver disease; NOV/CCN3

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test